Indeed, several studies have exploited the well‐established 4T1 breast cancer mouse model [14], known to naturally overexpress the murine CAIX (mCAIX) in hypoxic areas at later stages of tumour development, to study the role of CAIX in cancer progression [15] or evaluate novel therapies targeting CAIX [16]. This evidence concerns the gene CA9 and breast cancer.